Suppr超能文献

化疗药物诱导的肠道黏膜炎:病理生理学及潜在治疗策略

Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies.

作者信息

Dahlgren David, Sjöblom Markus, Hellström Per M, Lennernäs Hans

机构信息

Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Department of Neuroscience, Division of Physiology, Uppsala University, Uppsala, Sweden.

出版信息

Front Pharmacol. 2021 May 4;12:681417. doi: 10.3389/fphar.2021.681417. eCollection 2021.

Abstract

The gastrointestinal tract is particularly vulnerable to off-target effects of antineoplastic drugs because intestinal epithelial cells proliferate rapidly and have a complex immunological interaction with gut microbiota. As a result, up to 40-100% of all cancer patients dosed with chemotherapeutics experience gut toxicity, called chemotherapeutics-induced intestinal mucositis (CIM). The condition is associated with histological changes and inflammation in the mucosa arising from stem-cell apoptosis and disturbed cellular renewal and maturation processes. In turn, this results in various pathologies, including ulceration, pain, nausea, diarrhea, and bacterial translocation sepsis. In addition to reducing patient quality-of-life, CIM often leads to dose-reduction and subsequent decrease of anticancer effect. Despite decades of experimental and clinical investigations CIM remains an unsolved clinical issue, and there is a strong consensus that effective strategies are needed for preventing and treating CIM. Recent progress in the understanding of the molecular and functional pathology of CIM had provided many new potential targets and opportunities for treatment. This review presents an overview of the functions and physiology of the healthy intestinal barrier followed by a summary of the pathophysiological mechanisms involved in the development of CIM. Finally, we highlight some pharmacological and microbial interventions that have shown potential. Conclusively, one must accept that to date no single treatment has substantially transformed the clinical management of CIM. We therefore believe that the best chance for success is to use combination treatments. An optimal combination treatment will likely include prophylactics (e.g., antibiotics/probiotics) and drugs that impact the acute phase (e.g., anti-oxidants, apoptosis inhibitors, and anti-inflammatory agents) as well as the recovery phase (e.g., stimulation of proliferation and adaptation).

摘要

胃肠道特别容易受到抗肿瘤药物脱靶效应的影响,因为肠道上皮细胞增殖迅速,并且与肠道微生物群存在复杂的免疫相互作用。因此,在接受化疗的所有癌症患者中,高达40%-100%会出现肠道毒性,即化疗引起的肠道黏膜炎(CIM)。这种情况与干细胞凋亡以及细胞更新和成熟过程紊乱所导致的黏膜组织学变化和炎症有关。进而会引发各种病理状况,包括溃疡、疼痛、恶心、腹泻以及细菌易位败血症。除了降低患者生活质量外,CIM还常常导致剂量减少以及随后抗癌效果的降低。尽管经过了数十年的实验和临床研究,CIM仍然是一个尚未解决的临床问题,并且人们强烈共识需要有效的预防和治疗CIM的策略。对CIM分子和功能病理学理解的最新进展提供了许多新的潜在治疗靶点和机会。本综述概述了健康肠道屏障的功能和生理学,随后总结了CIM发生发展过程中涉及的病理生理机制。最后,我们强调了一些已显示出潜力的药理学和微生物干预措施。总之,必须承认迄今为止没有单一治疗方法能显著改变CIM的临床管理。因此,我们认为成功的最佳机会是采用联合治疗。最佳的联合治疗可能包括预防性药物(如抗生素/益生菌)以及影响急性期的药物(如抗氧化剂、凋亡抑制剂和抗炎剂)和恢复期的药物(如刺激增殖和适应)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/435d/8129190/32160144d245/fphar-12-681417-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验